Kura Oncology is rated Buy, driven by a strong cash position, strategic Kyowa Kirin partnership, and a robust, diversified pipeline. KURA's lead asset, Ziftomenib, targets AML and awaits a pivotal FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results